Compare Honeywell International Inc (HON) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honeywell International Inc vs Natera Inc. Common Stock — how do they compare? Honeywell International Inc trades at $208.11 (market cap $65.70B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Honeywell International Inc is the larger of the two by market cap, and Honeywell International Inc pays a 1.35% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Honeywell International Inc for 91 Days and Natera Inc. Common Stock for 0 Days on average.
| HON | NTRA | |
|---|---|---|
Market Cap | $65.70B | $57.03B |
Volume | 1,861,268 | 1,131,157 |
Sector | Industrials | Health |
52-Week High | $248.79 | $425.64 |
52-Week Low | $188.14 | $179.42 |
Typical Hold Time | 91 Days | 0 Days |
Enterprise Value | $90.49B | $56.18B |
Dividend Yield | 1.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Honeywell International (HON) trades at $207.61, down 0.97% on the day, as technical indicators show bearish momentum despite strong fundamentals. The company has consistently beaten earnings estimates in recent quarters with Q2 2026 EPS of $1.95 exceeding expectations of $1.83. Recent news highlights Honeywell's $300 million contract win for the Dangote refinery project and the company's strategic focus on automation following its corporate restructuring into three separate entities.
Honeywell presents a compelling value opportunity with attractive valuation multiples (P/E of 7.97, EV/EBITDA of 6.74) and strong profitability metrics (ROE 47.43%, net margin 21.58%). However, investors face risks from increasing debt levels and the execution challenges of the corporate spin-off strategy. Analyst consensus remains bullish with a $259.25 price target representing 25% upside potential from current levels.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
